Vertex Pharmaceuticals VRTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.03B+59.6% | $1.19B— | $1.08B+3.6% | $1.03B+129% | $646.3M-41.2% | ||
| $55.9M+15.5% | $55.7M+19.8% | $54M+1.5% | $51.7M-4.3% | $48.4M-9.5% | ||
| $166.4M+0.2% | $157.6M-6.1% | $194.9M+5.6% | $167.3M+8.5% | $166.1M-13.4% | ||
| -$39.8M-123% | $99.4M— | $59.9M+15.6% | $18.4M— | $169.6M-32.6% | ||
| $97.7M-41.5% | $77.4M-47.5% | $131.1M-28.2% | $148.6M+38.6% | $167.1M+109% | ||
| $35.6M+35.9% | $38.3M+356% | -$35.3M-153% | $7.6M+130% | $26.2M+26,100% | ||
| $23.1M+5.0% | $105.8M— | $83.9M-37.4% | -$63.2M+75.4% | $22M-86.9% | ||
| $1.43B+74.4% | $498M+504% | $1.24B+1,108% | $1.07B+129% | $818.9M-37.3% | ||
| $133.4M+228% | $149.4M+61.3% | $101.8M+50.4% | $145.7M+111% | $40.7M-40.5% | ||
| $2.51B+52.2% | $1.23B-43.0% | $1.35B-2.8% | $2.17B+67.6% | $1.65B-36.6% | ||
| -$431.9M-674% | -$288.1M+64.9% | -$117M+66.4% | -$484.5M-4.5% | -$55.8M+97.4% | ||
| $336.9M-20.9% | $128.4M-69.3% | $1.07B+248% | $391.8M+22.3% | $426.1M+225% | ||
| $228.5M-15.5% | $2.5M-65.8% | $91M+8.7% | $5.9M-92.7% | $270.5M+15.8% | ||
| -$538.8M+20.8% | -$77.2M+80.3% | -$1.15B-198% | -$349.2M+2.6% | -$680.4M-90.3% | ||
| -$40.3M-232% | $7.3M+115% | $0-100% | $57.2M+2,388% | $30.5M+296% | ||
| $417.1M+268% | $140M+121% | $0— | $296.6M+106% | $113.2M+109% | ||
| $3.2M+18.5% | $3M+11.1% | $3.2M-60.5% | $3.5M-63.9% | $2.7M-73.0% | ||
| $0-100% | $0— | $0— | $0— | $379M— | ||
| $70.5M+46.6% | -$664.5M— | $332.9M+95.1% | $166.6M-1.0% | $48.1M-75.2% | ||
| -$173.4M-717% | $250.6M+52.2% | $40.9M— | $76.4M-51.0% | $28.1M+128% | ||
| $5M+113% | -$23.1M-40.9% | $0+100% | -$57.8M-379% | -$39.2M-208% | ||
| $0-100% | $15.9M-48.5% | $0-100% | $4.3M-71.3% | $5.3M— | ||
| $2.21B+34.9% | $1.09B-25.2% | $1.33B+19.5% | $1.84B+55.5% | $1.64B+130% | ||
| $27M+61.7% | $54M+57.4% | $7.9M-6.0% | $49.1M-10.7% | $16.7M-1.2% | ||
| -$400K+20.0% | $1.1M+22.2% | $1.1M+22.2% | $2M+122% | -$500K-114% | ||
| $82.3M-55.4% | $389.4M+43.3% | $479.6M+72.2% | $513.3M+3.3% | $184.4M+430% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.29B+66.4% | $348.6M+276% | $1.14B+677% | $927.4M+124% | $778.2M-37.2% | ||
| $1.29B+66.4% | $348.6M+276% | $1.14B+677% | $927.4M+124% | $778.2M-37.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
